Eisai's High Dose Aricept Beats Expectations, But Lack Of Solutions Plague Mid-term Forecast

TOKYO - A higher-dose Aricept anti-Alzheimer treatment U.S. FDA approved this summer is set to be a core revenue contributor for Eisai through its business year ending next March and on, and if its endotoxin antagonist eritoran for severe sepsis is approved, the growth momentum could continue through 2012, according to Eisai and analysts